Abstract Background Elderly Chinese patients with advanced non-small cell lung cancer (NSCLC) often refuse chemotherapy due to the risk of intolerable grade 3–4 adverse events. This study aimed to evaluate the efficacy and safety of nivolumab plus ipilimumab in elderly patients with advanced NSCLC. Methods We retrospectively analyzed data from elderly patients with advanced NSCLC treated with nivolumab plus ipilimumab as initial or second-line therapy between May 2022 and December 2023 at The Tenth Affiliated Hospital, Southern Medical University, China. Tumor response and treatment toxicities were assessed based on the Response Evaluation Criteria in Solid Tumors version 1.1 criteria and National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Results A total of 5 elderly patients were included, with a median age of 82 years. All patients received nivolumab plus ipilimumab until disease progression, unacceptable toxicity, or unwillingness to continue treatment. The objective response rate (ORR) and disease control rate (DCR) were both 100%, and the median progression-free survival (PFS) was not reached. Treatment-related adverse events were generally mild, with the most common being pruritus (80%), rash (40%), and fatigue (40%). No grade 3 or higher toxicities were observed. Conclusions Nivolumab plus ipilimumab may provide durable ORR in elderly Chinese patients with advanced NSCLC, regardless of PD-L1 expression, with generally tolerable toxicities compared to standard chemotherapy.